2022
DOI: 10.1111/1751-7915.14022
|View full text |Cite
|
Sign up to set email alerts
|

Vaccine with bacterium‐like particles displaying HIV‐1 gp120 trimer elicits specific mucosal responses and neutralizing antibodies in rhesus macaques

Abstract: Preclinical studies have shown that the induction of secretory IgA (sIgA) in mucosa and neutralizing antibodies (NAbs) in sera is essential for designing vaccines that can effectively block the transmission of HIV-1. We previously showed that a vaccine consisting of bacterium-like particles (BLPs) displaying Protan-gp120AE-MTQ (PAM) could induce mucosal immune responses through intranasal (IN) immunization in mice and NAbs through intramuscular (IM) immunization in guinea pigs. Here, we evaluated the ability o… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
5

Relationship

1
4

Authors

Journals

citations
Cited by 6 publications
(3 citation statements)
references
References 54 publications
0
3
0
Order By: Relevance
“…The team evaluated the effectiveness of the vaccine by immunizing rhesus macaques in combination. In terms of mucosal immunity and systemic T cell immunity, BLPs-based vaccine showed significant advantages over BLPs alone (53). BLPs-RSVF, which displayed the respiratory syncytial virus (RSV) F protein on its surface, induced high levels of nasal sIgA and serum neutralizing antibodies than inactivated vaccines by immunizing BALB/c mice or cotton mice nasally, and significantly reduced lung viral load after a strong viral challenge.…”
Section: Viral Vaccinesmentioning
confidence: 99%
“…The team evaluated the effectiveness of the vaccine by immunizing rhesus macaques in combination. In terms of mucosal immunity and systemic T cell immunity, BLPs-based vaccine showed significant advantages over BLPs alone (53). BLPs-RSVF, which displayed the respiratory syncytial virus (RSV) F protein on its surface, induced high levels of nasal sIgA and serum neutralizing antibodies than inactivated vaccines by immunizing BALB/c mice or cotton mice nasally, and significantly reduced lung viral load after a strong viral challenge.…”
Section: Viral Vaccinesmentioning
confidence: 99%
“…Vaccines prepared using BLPs induce a robust local and systemic immune response, and this immune response is protective against infection by specific pathogens, including viruses, bacteria, and parasites. [ 17–22 ]…”
Section: Introductionmentioning
confidence: 99%
“…Vaccines prepared using BLPs induce a robust local and systemic immune response, and this immune response is protective against infection by specific pathogens, including viruses, bacteria, and parasites. [17][18][19][20][21][22] Herein, we constructed a TBEV BLPs vaccine (Figure 1) by displaying the TBEV E protein onto the surface of GEM via the anchoring region PA3 (3 represents the number of repeat motifs LysM) of peptidoglycan hydrolase. [23] The BLPs exhibited good dispersibility and high protein capacity, which are simple and inexpensive to prepare.…”
Section: Introductionmentioning
confidence: 99%